SCHEMBL5115416

SCHEMBL5115416

COc1cc([N+](=O)[O-])c(OC)cc1NC(=O)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC10A6 Q3KNW5 3/20 0.62
SLC10A2 Q12908 2/20 0.62
SLC10A1 Q14973 2/20 0.62
ALDH1A1 P00352 2/20 0.56
NPSR1 Q6W5P4 1/20 0.56
KCNMA1 Q12791 1/20 0.53
G6PD P11413 1/20 0.52
CRHBP P24387 1/20 0.52
CRHR2 Q13324 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MEN1 O00255 1/20 0.52
LMNA P02545 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
MAPK1 P28482 1/20 0.48
AVPR2 P30518 1/20 0.48
GPR27 Q9NS67 1/20 0.48
KCNA5 P22460 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5125625 0.87 KCNMA1 (0.71) SLC10A6SLC10A2SLC10A1ALDH1A1NPSR1
SCHEMBL5126801 0.86 KCNMA1 (0.61) SLC10A6SLC10A2SLC10A1ALDH1A1NPSR1
SCHEMBL5141365 0.82 ALDH1A1 (0.64) SLC10A6SLC10A2SLC10A1ALDH1A1NPSR1
SCHEMBL5119272 0.81 KCNMA1 (0.70) SLC10A6SLC10A2SLC10A1ALDH1A1KCNMA1
SCHEMBL5111933 0.79 MAPT (0.71) SLC10A6SLC10A2SLC10A1ALDH1A1KCNMA1
SCHEMBL5115491 0.79 SLC10A6 (0.59) SLC10A6SLC10A2SLC10A1ALDH1A1NPSR1
SCHEMBL5110439 0.78 SLC20A2 (0.59) SLC10A6SLC10A2SLC10A1ALDH1A1NPSR1
SCHEMBL5126148 0.77 MAPT (0.59) ALDH1A1NPSR1SMN1; SMN2MEN1LMNA
SCHEMBL15176790 0.76 SLC10A6 (1.00) SLC10A6SLC10A2SLC10A1ALDH1A1KCNMA1
SCHEMBL5111386 0.76 GPR27 (0.62) SLC10A6SLC10A2SLC10A1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351703-B2 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-01 US disclosed
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2005-04-14 US disclosed
US-6809089-B2 FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISORDERS SUCH AS HIGH BLOOD PRESSURE, ANGINA PECTORIS, CARDIAC INSUFFICIENCY, THROMBOSES OR ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-10-26 US disclosed
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed
US-6548547-B1 Cardiovascular disorders; hypotensive agents, antiasthmatics, cognition activators AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1A2 SLC10A6 2987/4885SLC10A2 1391/4885SLC10A1 1242/4885
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1B2 SLC10A6 3299/4885SLC10A2 1534/4885SLC10A1 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.